RecruitingPHASE1, PHASE2NCT07523555
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Studying Blastic plasmacytoid dendritic cell neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beijing Biotech
- Intervention
- Autologous CD19/CD22 dual-target CAR-T module(biological)
- Enrollment
- 96 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2026 – 2028
Study locations (1)
- Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07523555 on ClinicalTrials.govOther trials for Blastic plasmacytoid dendritic cell neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06006403Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell NeoplasmChongqing Precision Biotech Co., Ltd
- RECRUITINGNCT05430971Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT04216524Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03386513Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCNAbbVie
- RECRUITINGPHASE1NCT03113643SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Dana-Farber Cancer Institute
See all trials for Blastic plasmacytoid dendritic cell neoplasm →